Early Crohn’s disease: can we change the disease course?

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-05-14 DOI:10.1038/s41575-025-01072-w

Geert D’Haens, Melek Simsek

引用次数: 0

Abstract

Current treatments for Crohn’s disease prioritize early intervention with biological therapies, with several landmark trials demonstrating that starting biologic agents within the first years of diagnosis leads to superior patient outcomes. Although challenges remain, early use of biological treatments is increasingly supported in managing moderate to severe Crohn’s disease.

查看原文本刊更多论文

早期克罗恩病：我们能改变病程吗？

目前克罗恩病的治疗优先考虑生物治疗的早期干预，几项具有里程碑意义的试验表明，在诊断的头几年开始使用生物药物会导致更好的患者预后。尽管挑战依然存在，但在中度至重度克罗恩病的治疗中，早期使用生物疗法得到越来越多的支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.